By Fineline Cube 
Bayer AG (ETR: BAYN) released its 2025 financial results, recording EUR 45.6 billion (USD 52.84 billion) in group sales, up 1.1% on a currency‑ and portfolio‑adjusted basis year‑on‑year. The pharmaceutical division delivered 1.7% growth driven by oncology and cardiorenal blockbusters, offsetting steep declines in mature cardiovascular and ophthalmology franchises.
Regional Performance
| Region | Sales (EUR M) | Change (Fx & p adj.) | Commentary |
|---|---|---|---|
| North America | 16,725 | +5.1% | Strongest growth region; pharma pricing power offset consumer softness |
| Latin America | 7,831 | +4.7% | Market expansion in Consumer Health; currency tailwinds |
| Europe/Middle East/Africa | 13,501 | –3.5% | Xarelto generic erosion; consumer destocking |
| Asia/Pacific | 7,518 | –2.8% | China macro weakness; Eylea biosimilar competition |
Pharmaceuticals Division – Product‑Level Breakdown
| Product | Franchise | 2025 Sales (EUR M) | Change (YOY) | Driver/Headwind |
|---|---|---|---|---|
| Nubeqa (darolutamide) | Oncology | 2,385 (USD 2,764) | +62.4% | Metastatic prostate cancer label expansion; urology market share gains |
| Kerendia (finerenone) | Cardiorenal | 829 (USD 961) | +88.0% | Diabetic kidney disease guideline inclusion; cardio‑renal benefit data |
| Xarelto (rivaroxaban) | Cardiovascular | 2,344 (USD 2,716) | –31.6% | U.S. patent expiry (2024); generic erosion accelerating |
| Eylea (aflibercept) | Ophthalmology | 3,110 (USD 3,604) | –3.7% | Biosimilar entry (aflibercept‑szzs); intravitreal market share loss |
Division Total: EUR 17,829 million (+1.7% Fx & p adj.)
Consumer Health Division
| Metric | 2025 Performance |
|---|---|
| Sales | EUR 5,802 million (USD 6,723 million) |
| Growth | –0.1% (flat) |
| Pricing Impact | Moderate contribution; decelerating vs. prior years |
| Volume Trend | Stabilized overall |
| Regional Split | Growth: EMEA, Latin America; Decline: U.S., China (macro pressures) |
| Category Performance | All categories positive; Allergy/Cough/Cold only moderate gains |
Strategic Outlook & Investor Takeaways
- Growth Engine Transition: Nubeqa and Kerendia combined contributed EUR 3.2 billion (+68% blended growth), partially offsetting EUR 1.1 billion Xarelto decline – demonstrating successful pipeline execution amid LOE (loss‑of‑exclusivity) cycle
- Patent Cliff Management: Xarelto erosion expected to deepen in 2026; management guided for continued Nubeqa/Kerendia acceleration to stabilize pharma margins
- Consumer Health Reset: Flat performance reflects pricing normalization post‑inflationary period; China recovery timeline uncertain
- Capital Allocation: Bayer reiterated commitment to EUR 3 billion annual R&D in pharma; no share buyback announcement; dividend policy under review given litigation overhang
Forward‑Looking Statements
This brief contains forward‑looking statements regarding product performance, regional growth, and strategic priorities based on Bayer’s 2025 financial disclosures. Actual results may differ due to currency fluctuations, competitive dynamics, regulatory changes, and macroeconomic conditions.-Fineline Info & Tech